

PHARMACEUTICAL 2023

IDEAYA Biosciences Inc. Rank 39 of 446









RealRate

IDEAYA Biosciences Inc. Rank 39 of 446



The relative strengths and weaknesses of IDEAYA Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of IDEAYA Biosciences Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 61% points. The greatest weakness of IDEAYA Biosciences Inc. is the variable Intangible Assets, reducing the Economic Capital Ratio by 3.6% points.

The company's Economic Capital Ratio, given in the ranking table, is 254%, being 211% points above the market average of 43%.

| Input Variable                              | Value in<br>1000 USD |
|---|----------------------|
| Assets, Current                             | 370,454              |
| Cost of Goods Sold                          | 0                    |
| Intangible Assets                           | 0                    |
| Liabilities, Current                        | 31,718               |
| Liabilities, Non-Current                    | 6,796                |
| Other Assets                                | 11,006               |
| Other Compr. Net Income                     | -2,159               |
| Other Expenses                              | 0                    |
| Other Liabilities                           | 0                    |
| Other Net Income                            | 3,847                |
| Other Revenues                              | 50,931               |
| Property and Equipment                      | 6,509                |
| Research and Development                    | 89,536               |
| Selling, General and Administrative Expense | 23,897               |

| Output Variable          | Value in<br>1000 USD |
|--------------------------|----------------------|
| Assets                   | 387,969              |
| Liabilities              | 38,514               |
| Expenses                 | 113,433              |
| Revenues                 | 50,931               |
| Stockholders Equity      | 349,455              |
| Net Income               | -58,655              |
| Comprehensive Net Income | -59,734              |
| Economic Capital Ratio   | 254%                 |

